News in research & treatment

---

A company is trying to create a permanent, 

one-off treatment for FH using gene technology:

 "Verve is developing a single-dose base-editing treatment for heterozygous familial hypercholesterolemia (HeFH)... the only in vivo base-editing candidate... specifically designed to permanently switch off the PCSK9 gene in the liver, to durably lower disease-driving low-density LDL-C. "

 News: Clinical Update: First Trial of Base-Editing Therapy Lowers Cholesterol in Humans - CRISPR Medicine (crisprmedicinenews.com) 

(https://crisprmedicinenews.com/news/clinical-update-first-trial-of-base-editing-therapy-lowers-cholesterol-in-humans/)